After early hiccups in manufacturing, Adverum outlines plans for commercial gene therapy plant in North Carolina hub
After some early hiccups in its manufacturing procedures for its gene therapy drug targeting wet age-related macular degeneration, California biotech Adverum has addressed those concerns and is priming the pump for a commercial launch.
The ocular and other rare disease-focused gene therapy company will invest $80 million in a new cGMP manufacturing facility in North Carolina’s bustling Research Triangle Park that by 2023 will be ready to manufacture commercial supply of ADVM-022, Adverum’s intravitreal therapeutic, the company said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.